Greffex

Greffex is a biotechnology company specializing in the development of vaccines and gene therapies through its proprietary GREVAX platform. The GREVAX system utilizes an engineered adenoviral vector to deliver genetic material, enabling a "plug-and-play" approach for rapid vaccine production. This technology eliminates the need for traditional manufacturing methods like egg-based or cell-culture systems, allowing for faster response times to emerging infectious diseases. The company's pipeline includes candidates for COVID-19, influenza, MERS, and Ebola, as well as treatments for organ transplant rejection. Greffex aims to provide scalable and cost-effective solutions for global health challenges and biodefense.